Efzimfotase alfa shows positive Phase III results in hypophosphatasia
Efzimfotase alfa demonstrated significant improvement in bone health in treatment-naïve pediatric patients and maintained safety in those previously treated with Strensiq.
Asset / Drug
Drug and asset intelligence for Hypophosphatasia with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.